The Trump administration this month scrapped a Biden-era proposal that would have required state Medicaid programs and ...

President Donald Trump is under pressure to decide how widely available anti-obesity drugs should be and whether Medicare should cover them.

UB researcher Nicole Albanese talks about recent developments, including the end of the shortage of weight-loss drugs and the ...

Independence Health Group, the parent company of Independence Blue Cross, spent $500 million last year to provide ...

Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Novo Nordisk partners with telehealth ...

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

CVS reported first quarter earnings Thursday, blowing past Wall Street's expectations and ending anxiety over Medicare Advantage headwinds.